Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalPsychiatryMental HealthTrial Update

ACT vs CBT Trial for Psychological Distress in HIV/AIDS Patients

This trial is significant as it explores psychological interventions for HIV/AIDS patients, a population that often faces stigma and mental health challenges. The outcomes could reshape treatment protocols and influence portfolio strategies for companies in the mental health space.

Published: June 18, 2026
Updated: June 18, 2026
Author: Humanexa Intelligence
Therapeutic area: Psychiatry / Mental Health
Company: Pfizer
Asset: Truvada
Trial SummaryCLN

Phase III

Psychiatry / Mental Health

Status

Active

Sponsor

Pfizer

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

This trial is significant as it explores psychological interventions for HIV/AIDS patients, a population that often faces stigma and mental health challenges. The outcomes could reshape treatment protocols and influence portfolio strategies for companies in the mental health space.

Why it matters

This trial is significant as it explores psychological interventions for HIV/AIDS patients, a population that often faces stigma and mental health challenges. The outcomes could reshape treatment protocols and influence portfolio strategies for companies in the mental health space.

What changed

Trial Update

Analysis

A randomized controlled trial is underway comparing Acceptance and Commitment Therapy and Cognitive Behavioral Therapy in HIV/AIDS patients.

This trial is significant as it explores psychological interventions for HIV/AIDS patients, a population that often faces stigma and mental health challenges. The outcomes could reshape treatment protocols and influence portfolio strategies for companies in the mental health space.

Monitor outcomes related to depression, anxiety, and stigma, as well as the overall effectiveness of ACT vs CBT in this population.

Related companies & assets

Companies

  • Pfizer →

Assets

  • Truvada →
  • HIV/AIDS →

Sources & Humanexa intelligence

Source links

  • Comparison of Acceptance and Commitment Therapy and Cognitive Behavior Therapy: Managing Psychological Distress and Its Multifaceted Impact on Stigmatization, Psychological Wellbeing, Social Support ↗
  • ACT vs CBT Trial for Psychological Distress in HIV/AIDS Patients ↗

Related Humanexa pages

  • ACT vs CBT Trial for Psychological Distress in HIV/AIDS Patients →

Related signals

Trial SummaryCLN

Phase III

Hepatology / Liver Fibrosis

Status

Active

Signal Score

8.4

Clinicalhigh signal

Novel Oral Nanoemulsion Targets Hepatic Stellate Cells in Liver Fibrosis Treatment

A vitamin A-functionalized self-nanoemulsifying drug delivery system effectively targets hepatic stellate cells in liver fibrosis.

June 20, 2026Read signal →
Trial SummaryCLN

Phase III

Infectious Disease / HIV

Status

Initiated

Signal Score

8.2

Clinicalhigh signal

Study on Intestinal TRM Cells and HIV-1 Persistence During ART Launched

A new study aims to characterize intestinal tissue-resident memory T cells in HIV-1 patients on ART, focusing on their role in viral persistence.

June 20, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.